Metabolic
Semaglutide
Ozempic · Wegovy · Rybelsus · GLP-1 · agonist
A licensed GLP-1 medicine for type-2 diabetes and weight management — the one item here with strong human evidence and a clear Rx route.
Reference status
Editorial research · independent review pending · 4 claims graded
What it is
Semaglutide is a GLP-1 receptor agonist and, unlike the research peptides on this list, it is a fully licensed prescription medicine with large phase-3 trials behind it (the STEP and SUSTAIN programmes).
We include it because people search for it alongside 'peptides', but it belongs in a completely different lane: it is a regulated medicine that should only be used under medical supervision. Sourcing it outside the prescription system carries real safety and legal risk.
The science, graded
What’s claimed — and how strong the evidence behind each claim actually is.
“Produces significant weight loss”
Large RCTs (STEP) show ~15% average body-weight reduction. This is well established.
Claim-level citation mapping is in progress.
“Improves blood-sugar control in type-2 diabetes”
Core licensed indication, supported by the SUSTAIN trial programme.
Claim-level citation mapping is in progress.
“Reduces cardiovascular events”
Growing outcome data (e.g. SELECT) is positive; discuss specifics with a clinician.
Claim-level citation mapping is in progress.
“Safe to self-source and self-dose”
This is the dangerous claim. It is a medicine with real side effects and needs proper supervision.
Claim-level citation mapping is in progress.
Legal and regulatory context
Separate summaries for Great Britain, the United States, and the European Union. These are preliminary research summaries awaiting independent regional review; they are not legal determinations or advice.
Great Britain
Prescription-only medicine (POM) in the UK, available via GPs and regulated weight-management services. Buying unlicensed 'semaglutide' from research suppliers is unsafe and outside the law.
This is preliminary regulatory research, not a reviewed legal determination or legal advice.
United States
Regional legal and regulatory review required before publication.
This is preliminary regulatory research, not a reviewed legal determination or legal advice.
- FDA's Concerns About Unapproved Drugs · U.S. Food and Drug Administration
European Union
Regional legal and regulatory review required before publication.
This is preliminary regulatory research, not a reviewed legal determination or legal advice.
- Buying medicines online · European Medicines Agency
What the community says
Enormous mainstream and social discussion. Communities are split between people using it via legitimate prescriptions and warnings about grey-market 'research' semaglutide of unknown quality.
Where they’re talking
- News & socialHigh-profile weight-loss coverage.
- r/SemaglutidePrescription users share dosing/side-effect experiences.
References
- 1.Supply unlicensed medicinal products (specials) · MHRA
- 2.FDA's Concerns About Unapproved Drugs · U.S. Food and Drug Administration
- 3.Buying medicines online · European Medicines Agency